CAMBRIDGE, MA / ACCESSWIRE / March 26, 2024 / Moderna, Inc. (NASDAQ: MRNA) announced that mRNA-1283, the company’s next-generation COVID-19 vaccine, effectively met the number one endpoint in its Phase 3 clinical trial, demonstrating a superior immune reaction to SARS-CoV-2 compared to mRNA-1273. 222, Moderna’s legal COVID-19 vaccine.
“We are excited to announce our fourth infectious disease vaccine program with positive Phase 3 data, validating our mRNA platform,” said Stéphane Bancel, president and chief executive officer of Moderna. 19, mRNA-1083, and this milestone gives us confidence in our ability to commercialize this much-needed vaccine.
In the pivotal Phase 3 NextCOVE (NCT05815498 trial, mRNA-1283 was shown to elicit a superior immune reaction opposite to Omicron BA. 4/BA. 5 and the original strains of the SARS-CoV-2 virus, compared to mRNA-1273. 222. It is vital to note that this reaps the maximum advantages seen in participants over the age of 65, the population that remains at highest risk for severe outcomes from COVID-19. Maximum adverse local pain commonly reported at the injection site. Commonly reported peak systemic pain adverse occasions included headache, fatigue, myalgia, and chills.
The NEXTCove clinical trial is a randomized, blinded, observer-controlled study of approximately 11,400 people aged 12 years and older in the United States, the United Kingdom, and Canada. mRNA-1283 has been shown to have a protection profile against Moderna-approved COVID-19 vaccines.
The storage, shelf life, and prefilled syringe presentation of mRNA-1283 can reduce the burden on healthcare providers and potentially develop new parameters in the service of public health. Detailed research of knowledge from the Phase 3 clinical trial of mRNA-1283 will be shared at the company’s Vaccine Day on March 27 and presented at upcoming clinical conferences.
About Moderna
Moderna is a leader in creating mRNA-based medicines. Through advancements in mRNA technology, Moderna is reinventing the way drugs are made and transforming the way we treat and prevent disease for everyone. Working at the intersection of science, technology, and fitness for more than a decade, the company has developed drugs with unprecedented speed and efficiency, adding one of the earliest and most effective COVID-19 vaccines.
Moderna’s mRNA platform has enabled the advancement of therapies and vaccines against infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases. With an exclusive culture and a global team driven through Moderna’s values and mindset to responsibly replace the long-term of human health. Moderna strives to achieve the greatest effect imaginable on other people through mRNA drugs. To learn more about Moderna, visit modernatx. com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube, and LinkedIn. .
Spikevax® is a registered trademark of Moderna.
Forward-Looking Statements
This press release comprises forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and adds statements regarding: the possible longer useful life of the refrigeration and garage benefits of mRNA-1283 in connection with Spikevax; and the ability of mRNA-1283 to maintain its effectiveness compared to Spikevax. The forward-looking statements contained in this press release are neither promises nor guarantees, and you should not place undue reliance on such forward-looking statements because they involve known and unknown dangers, uncertainties and other matters, many of which are not known. under Moderna’s terms and which may cause actual effects to differ materially from those expressed or implied by such forward-looking statements. These hazards, uncertainties and other items include, but are not limited to, the hazards and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the United States Securities and Exchange Commission. Exchange Commission (SEC), as well as Moderna’s upcoming filings with the SEC, which will be found on the SEC’s online website at www. sec. gov. Except as required by law, Moderna disclaims any objective or duty to update or revise any forward-looking statements contained in this press release whether as a result of new information, long-term developments or otherwise. These forward-looking statements are based on Moderna’s existing expectations and speak only as of the date of this press release.
Moderna Contacts
Media:Elise MeyerSr. Director of Corporate Communications 1 617-852-7041Elise. Meyer@modernatx. com
Investors: Lavina TalukdarSenior Vice President and Head of Investor Relations 1 617-209-5834Lavina. Talukdar@modernatx. com
SOURCE: Moderna, Inc.